{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-038778","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.445764+00:00","generated_at":"2026-06-17T09:54:47.557292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Theriva Biologics reports $41.8M cash, Q4 2022 results; VCN-01 trials advance","bullets":["Cash and equivalents $41.8M as of Dec 31, 2022, down from $67.3M; runway into Q3 2024.","G&A expenses $9.9M (+50.8% YoY); R&D expenses $11.7M (+50% YoY) driven by VCN-01 trials.","First patient dosed in VIRAGE Phase 2b trial of VCN-01 for metastatic pancreatic cancer (Jan 2023).","First patient dosed in investigator-sponsored Phase 1 trial of VCN-01 for brain tumors (Jan 2023).","SYN-004 Phase 1b/2a in allo-HCT: blinded safety/PK data presented at Tandem Meetings (Feb 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-038778","json":"https://secwatch.observer/filing/0001104659-23-038778.json","markdown":"https://secwatch.observer/filing/0001104659-23-038778.md","text":"https://secwatch.observer/filing/0001104659-23-038778.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465923038778/0001104659-23-038778-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465923038778/tm2310776d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:54:47.557292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81c453e4e429b91bb5f09de17d6e8d64901244f0","claim":"Theriva Biologics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, Theriva Biologics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465923038778/0001104659-23-038778-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}